Busy. Please wait.
Log in with Clever
or

show password
Forgot Password?

Don't have an account?  Sign up 
Sign up using Clever
or

Username is available taken
show password


Make sure to remember your password. If you forget it there is no way for StudyStack to send you a reset link. You would need to create a new account.
Your email address is only used to allow you to reset your password. See our Privacy Policy and Terms of Service.


Already a StudyStack user? Log In

Reset Password
Enter the associated with your account, and we'll email you a link to reset your password.

Rheumatology

Quiz yourself by thinking what should be in each of the black spaces below before clicking on it to display the answer.
        Help!  

Question
Answer
SLE prevalence   90% of all pts = women; occur in all sexes, age / ethnic; US: 15-50/100,000 (highest: AA females)  
🗑
SLE epi   urban > rural; tripled in 40 yrs; M: less photosensitivity, more serositis; Elderly: milder disease  
🗑
SLE age of onset   20% < 16; 65% btw 16-55; 15% >55  
🗑
SLE pathophysiology   >100 genes; many environ factors; UV light (triggers photosensitivity rashes); drugs (sulfonamides); SMK; infxn (EBV, ?parvo B-19); hormones  
🗑
SLE pathogenesis: 5 stages   1: Susceptibility 2: innate/adaptive immune responses 3: AutoAbs, immune complexes (complexes trigger complement) in visceral tissue capillaries 4: inflammation 5: tissue damage  
🗑
SLE genl clinical findings   systemic, cardiopulmonary; GI, Neuropsychiatric; derm  
🗑
SLE: Cardiopulmonary findings:   pleuritis/pl effusion / serositis; pericarditis / effusion; interstitial pneumonia; pulmo HTN  
🗑
SLE: GI findings:   hepatitis; HSM; esophageal dysmotility; pancreatitis  
🗑
SLE: Neuropsychiatric findings:   cognitive impairment; HA  
🗑
SLE: Derm findings:   photosensitivity; malar rash; discoid lesions; nonspecific maculopapular lesions; ulcers of oral, genital, nasal mucosa; alopecia  
🗑
most serious manifestation of SLE =   renal disease; may be asx early; leading cause of mortality  
🗑
SLE classic renal manifestation =   nephritis (histo classed as I-VI); 50% pts also develop nephrotic syn; untx’d nephritis can lead to ESRD in 2 years  
🗑
SLE classic MS presentation   polyarthritis similar in distribution to RA; non-erosive, non-deforming; pt sx may be disproportionate to physical findings; also: ischemic necrosis; myalgias  
🗑
most common SLE clin findings   systemic; arthralgias/myalgias; photosensitivity; malar rash; cognitive impairment  
🗑
Most common Ab’s assoc with SLE   ANA (best screening test); dsDNA (hi titer diagnostic); anti-Smith (specific not sensitive); anti-RNP (not spec for SLE); Ro, La. False pos VDRL  
🗑
Drug-induced lupus =   Syndrome of pos ANA assoc w/ constellation of sx (malaise, fever, arthritis +/-myalgias, rash, serositis); autoimmune-mediated response; W > AA; renal/ CNS sx rare; MANY causative drugs  
🗑
DILE: dx criteria   1 or more SLE clinical sx; pos ANA; no hx SLE before suspected drug; drug taken 3 wks-2 yrs prior to sx; Drug withdrawal led to sx improvement  
🗑
acute cutaneous lupus =   localized or generalized; usu do have systemic dz (3 forms: classic malar rash; genl erythema; bullous dz)  
🗑
subacute cutaneous lupus =   annular or papulosquamous (AKA psoriaform: sl raised)  
🗑
chronic cutaneous lupus =   discoid lupus; host of nonspecific LE lesions  
🗑
Prevalence of systemic lupus in cutaneous lupus pts   Acute: 100% have systemic lupus; Subacute: 50%; Chronic cutaneous: 25%  
🗑
Discoid lesions: incidence   develop in 25% of SLE pts; also may occur in absence of any other clinical manifestations  
🗑
DLE pt: risk of developing SLE   DLE pt 5-10% risk of developing SLE which tends to be mild  
🗑
Patients with DLE: number of discoid lesions:   Increased number of lesions correlates with increased risk (of developing SLE)  
🗑
DLE common sites   face, neck, scalp  
🗑
SLE tx:   Systemic glucocorticoids (mainstay of life-threatening manifestations); major organ involvement guides tx options  
🗑
SLE: tx: mild-moderate MS sx   NSAIDs  
🗑
SLE: tx: cutaneous & mild-moderate MS sx   Anti-malarials (mostly hydroxychloroquinine)  
🗑
SLE: tx: mod-severe dz (major organ involvemt) or severe/ refractory dz w/o organ involvemt   Azathioprine, methotrexate, cyclophosphamide, (CellCept)  
🗑
Fibromyalgia & SLE   50% of patients with lupus have fibromyalgia  
🗑
Livedo reticularis seen in:   SLE; APS  
🗑
MCTD Sx:   severe Raynaud; swollen, puffy hands, arthritis; nail capillary changes; may have any/ many sx of SLE & scleroderma  
🗑
MCTD Testing:   pos anti-RNP Ab  
🗑
MCTD Tx   like SLE & scleroderma, depending on sx  
🗑
UCTD   Lupus-Light; a few sx like autoimmune, but not enough to fulfill the dx; usu pts won’t progress to lupus  
🗑
SLE Dx criteria   must meet 4 of 11 criteria: malar, discoid, photosensitivity, oral ulcers, arthritis, serositis (ht,lung, peritoneal), renal, ANA, hemo, imm dz (anti-DNA, anti-Sm), neuro  
🗑
Drugs that precipitate SLE flare   procainamide, hydralazine, INH, methyldopa, quinidine, chlorpromazine, cimetidine, HCTZ; penicillin; sulfonamides; terbinafine  
🗑
SLE pathophysiology   >100 genes; many environ factors; UV light; sulfonamides; SMK; EBV, ?parvo B19); hormones  
🗑
SLE: Cardiopulmonary findings:   pleuritis/pl effusion / serositis; pericarditis / effusion; interstitial pneumonia; pulmo HTN  
🗑
SLE: GI findings:   hepatitis; HSM; esophageal dysmotility; pancreatitis  
🗑
SLE: Derm findings:   photosensitivity; malar rash; discoid lesions; nonspecific maculopapular lesions; ulcers of oral, genital, nasal mucosa; alopecia; occur in almost all SLE pts  
🗑
Mixed Connective Tissue Dz defn   overlap syndrome of lupus & scleroderma  
🗑
Mixed Connective Tissue Dz Sx:   severe Raynaud; swollen, puffy hands, arthritis; nail capillary changes; may have any/ many sx of SLE & scleroderma  
🗑
Collagen vascular dz includes:   RA, SLE, Scleroderma, Dermatomyositis, Polyarteritis nodosa  
🗑
Female with arthralgias, malar rash, +ANA, + anti-double stranded DNA Abs, +anti-phospholipid Abs =   SLE  
🗑
Dusky red, well localized single or multiple papules or plaques usually of face   Discoid lupus  
🗑
SLE tx:   Exercise & sun protection; Systemic glucocorticoids (mainstay of life-threatening sxs); major organ involvement guides tx options  
🗑
SLE: tx: mild-moderate MS sx   NSAIDs  
🗑
SLE: tx: cutaneous & mild-moderate MS sx   Anti-malarials (mostly hydroxychloroquinine), c'steroids  
🗑
SLE: tx: mod-severe dz (major organ involvemt) or severe/ refractory dz w/o organ involvemt   Azathioprine, methotrexate, cyclophosphamide, mycophenolate (CellCept)  
🗑


   

Review the information in the table. When you are ready to quiz yourself you can hide individual columns or the entire table. Then you can click on the empty cells to reveal the answer. Try to recall what will be displayed before clicking the empty cell.
 
To hide a column, click on the column name.
 
To hide the entire table, click on the "Hide All" button.
 
You may also shuffle the rows of the table by clicking on the "Shuffle" button.
 
Or sort by any of the columns using the down arrow next to any column heading.
If you know all the data on any row, you can temporarily remove it by tapping the trash can to the right of the row.

 
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.

  Normal Size     Small Size show me how
Created by: Abarnard
Popular Medical sets